IBD-Associated Arthritis News

This past spring, two studies shed light on how some of the largest clinician organizations and publishers in rheumatology, including the American College of Rheumatology and EULAR, have failed to provide adequate training materials or clear guidelines when it comes to caring for patients of color.

Findings from the Live Yes! INSIGHTS survey from the Arthritis Foundation showed that out of some 40,000 patient responses, 100% reported experiencing some kind of pain within the last 7 days.

Anti-COVID-19 antibody responses are attenuated in patients who receive infliximab for inflammatory bowel disease, according to a speaker at the 2021 Interdisciplinary Autoimmune Summit.

Undeterred by the FDA’s rejection of filgotinib over testicular toxicity concerns, the United Kingdom’s National Institute for Health and Clinical Excellence has endorsed its use among eligible patients on England’s National Health Service.

Drug maker Gilead Sciences has announced it will no longer pursue FDA approval for its janus kinase inhibitor filgotinib in the treatment of rheumatoid arthritis, according to a company press release.

Therapeutic drug monitoring, in which treatments were individually assessed and reviewed, failed to improve remission for patients with a variety of rheumatic diseases who started infliximab, according to a speaker at ACR Convergence.

How common is asymptomatic bowel involvement in patients with peripheral or axial SpA? Can we use NSAIDs in these patients? What’s the difference between sulfasalazine and mesalamine? Hear what a rheumatologist should know about IBD!

The percentage of adult arthritis visits to office-based physicians increased significantly during 2006-2015, with the percentage of visits where opioids were prescribed also increasing during that time, according to data.

COVID-19 outcomes are worse among patients with inflammatory arthritis receiving glucocorticoids, but not in those receiving anticytokine therapy, according to data published in Arthritis & Rheumatology.

The COVID-19 pandemic, in places like Detroit, with a large working-class population, can highlight the gap between the rich and the poor. It can demonstrate how political unrest can impact the response to a critical situation. Moreover, it can show how health care workers can face both personal and professional challenges in managing an outbreak of this magnitude.